Beacon Therapeutics is dedicated to transforming lives through innovative ocular gene therapy. Their mission is to save and restore vision for patients with various retinal diseases, both common and rare, that lead to blindness. The company focuses on diseases such as X-Linked Retinitis Pigmentosa (XLRP), Dry Age-related Macular Degeneration (dAMD), and Cone Rod Dystrophy (CRD).

Their groundbreaking AAV gene therapy works by adding a functional copy of the mutated gene, enabling the body to produce necessary proteins and offering long-lasting benefits. This approach has the potential to significantly improve the quality of life for patients.